Rippon Ubhi appointed Chair of the European Medicines Group
Reading, 15 November 2024. Sanofi today announced that Rippon Ubhi has been appointed as the new Chair of the European Medicines Group (EMG). Rippon will continue her role as Country Lead for Sanofi UK & Ireland alongside this new appointment.
Rippon has extensive experience of shaping healthcare systems to support better patient access to innovative medicines. She brings close to 20 years of senior commercial leadership experience in global, international (emerging markets including China) and affiliate organisations including having lived and worked in Japan, United States and the UK over the past decade, working across pre-launch, launch and established business & culture environments. She joined Sanofi in late 2022 after 18 years at AstraZeneca and has since played a pivotal role in leading the UK & Ireland business to success.
The European Medicines Group (EMG) represents 22 continental European headquartered research-based pharmaceutical companies, which together are significant investors and employers in the UK and make a major contribution to the NHS and its ability to deliver better patient outcomes across a broad range of conditions. The EMG works closely with the industry’s trade body, the Association of the British Pharmaceutical Industry and works with the UK Government, the NHS and wider stakeholders for the benefit of patients.
As Chair of the EMG, Rippon will play a crucial role in shaping the group's strategic direction and priorities. She will lead efforts to advocate for policies that support the development and timely access to innovative medicines in the UK. A key focus of her role will be supporting initiatives that position the UK as a world-leading base for life sciences, attracting investment and fostering innovation. Through these efforts, Rippon will ensure that the EMG continues to be an influential voice in discussions about the future of healthcare and life sciences in the UK.
Rippon Ubhi
Country Lead for Sanofi UK & Ireland
"I am honoured to take on the role of Chair of the European Medicines Group at such an exciting time for our industry. This is a great opportunity to contribute to shaping the future of healthcare in the UK and to work towards our shared goal of improving patients' lives. As Chair, I will be working closely with EMG members, the government and NHS to make the UK a Life Sciences superpower which provides faster access to innovative medicines and vaccines, attracts inward investment, and drives economic growth.”
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Contacts
Nick Murphy, Corporate Communications Lead, Sanofi UK & Ireland
+44 (0) 7591 596385 | nick.murphy@sanofi.com
Clara Bentham, Head of Corporate Affairs, Sanofi UK & Ireland
+44 (0)7841 033734| clara.bentham@sanofi.com
